Research Journal of Oncology Open Access

A Novel Therapeutic Strategy for the Treatment of Metastatic Colorectal Cancer

Gil Joan^* Department of Oncology, Griffith University, Australia
^*Correspondence: Gil Joan, Department of Oncology, Griffith University, Australia, Email:

Received: 01-Mar-2023, Manuscript No. IPRJO-23-16138; Editor assigned: 03-Mar-2023, Pre QC No. IPRJO-23-16138 (PQ); Reviewed: 17-Mar-2023, QC No. IPRJO-23-16138; Revised: 22-Mar-2023, Manuscript No. IPRJO-23-16138 (R); Published: 29-Mar-2023, DOI: 10.36648/iprjo-7.1.06

Introduction

Colon cancer accounts for approximately 10% of all cancers and is the second leading cause of cancer death. Proper clinical management of these patients remains a difficult medical problem. Much effort has been expended to elucidate the molecular structure of metastatic colorectal cancer. This has led to the identification of multiple drug-activated tumor molecular targets with the aim of developing individualized therapies for each patient. This article summarizes the improvements in clinical management of patients with metastatic colorectal cancer in the rise of precision medicine. Indeed, the molecular stratification on which current treatment algorithms for metastatic colorectal cancer are based does not fully reflect the complexity of the disease, but implementation of more effective therapeutic approaches is clinically relevant. This was the first important step towards genetically meaningful profiles. This has resulted in clinically relevant improvements in metastatic colorectal cancer control and patient survival. The next step in the clinical management of metastatic colorectal cancer is a comprehensive study on the precise application of tumor genetic alterations, tumor and the microenvironment gene and protein expression profiles, host immune competence, and the resulting dynamic changes to medicine. Integrate knowledge. Continuing care for each patient based on this approach This approach leads to the identification of individual prognostic and predictive parameters, allowing physicians to select the most appropriate treatment program for each patient with metastatic colorectal cancer throughout the disease course helps.

Description

Treatment of patients with metastatic colorectal cancer has evolved significantly over the past two decades. Numerous therapies are currently available as first-line treatment for metastatic colorectal cancer. Advanced molecular techniques have been developed to reveal new prognostic and predictive biomarkers for colorectal cancer. The development of next-generation sequencing and whole-exome sequencing is a powerful new tool for discovering predictive molecular biomarkers that will facilitate the delivery of personalized therapeutics and represents a major breakthrough in DNA sequencing technology in recent years. is spurring on. Appropriate adjuvant therapy for patients with metastatic colorectal cancer is determined by tumor stage, presence of high-risk pathologic features, microsatellite instability status, patient age, and performance status. Chemotherapy, targeted therapy, and immunotherapy are the main systemic therapies for patients with metastatic colorectal cancer. Despite the fact that these new treatment options have improved overall survival in metastatic colorectal cancer, survival in non-metastatic disease remains optimal. Molecular techniques currently used to support our ability to practice personalized medicine.

Conclusion

Treatment of patients with metastatic colorectal cancer has advanced significantly over the past two decades. In particular, today there are a wide range of options for first-line treatment of metastatic colorectal cancer. Advanced molecular techniques have been developed to identify new prognostic and predictive biomarkers in metastatic colorectal cancer. DNA sequencing technology has made remarkable progress in recent years. This is largely a result of the development of next-generation sequencing and whole-exome sequencing, which are powerful new tools for the discovering predictive molecular biomarkers that will facilitate the delivery of personalized medicine. In addition to tumor tissue, recent efforts have focused on the analysis of circulating tumor DNA in peripheral blood.